RNA

Avidity Biosciences, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.14
52-Week Range: $7.68 – $16.77
Market Cap: $134.11M
P/E (TTM): —
EPS (TTM): -5.44
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.63
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: -56.37%
Operating Margin: -752.93%
Profit Margin: -184.15%
Current Ratio: 8.73
Debt/Equity: 0.01
Total Debt: $1.68M
Free Cash Flow: —
Revenue Growth: -21.90%
Earnings Growth: —
Enterprise Value: $-128.11M

RNA Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$9.76M	$10.90M	$18.62M
Research & Development	$12.65M	$19.20M	$53.76M
Selling, General & Admin	$3.50M	$4.92M	$41.68M
Operating Expenses	$16.15M	$24.11M	$95.43M
Operating Income	-$6.39M	-$13.22M	-$76.81M
EBITDA	-$6.25M	-$13.05M	-$76.49M
Pretax Income	-$6.38M	-$13.22M	-$76.83M
Income Tax	$0.00	$11.91M	-$142.00K
Net Income	-$6.38M	-$25.12M	-$76.68M
Diluted EPS	-0.37	-1.47	-2.89
Diluted Shares	17.12M	17.12M	17.11M

RNA Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	—	—	$270.00M
Receivables	$751.00K	$0.00	—
Current Assets	$856.00K	$483.00K	$272.85M
Total Assets	$10.29M	$7.19M	$278.35M
Current Liabilities	$33.80M	$26.80M	$41.80M
Total Debt	$9.85M	$6.80M	$3.67M
Total Liabilities	$80.91M	$68.29M	$71.07M
Shareholders' Equity	-$70.62M	-$61.11M	$207.29M
Working Capital	-$32.95M	-$26.32M	$231.04M

RNA Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	$56.39M	-$22.55M	-$41.13M
Capital Expenditure	-$320.00K	-$266.00K	-$1.45M
Free Cash Flow	$56.07M	-$22.82M	-$42.57M
Depreciation & Amortisation	$138.00K	$172.00K	$323.00K
Stock-Based Compensation	$2.51M	$3.18M	$7.68M
Investing Cash Flow	-$320.00K	-$266.00K	-$1.45M
Financing Cash Flow	-$56.07M	$22.82M	$42.57M

RNA Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.97M	$1.57M	$3.85M	$12.34M	$859.00K	$19.64M	$3.00M
Research & Development	$21.45M	$6.94M	$13.29M	$15.03M	$18.50M	$16.66M	$15.34M
Selling, General & Admin	$25.78M	$2.09M	$3.42M	$5.77M	$30.40M	$20.26M	$10.28M
Operating Expenses	$47.22M	$9.03M	$16.71M	$20.80M	$48.89M	$36.91M	$25.62M
Operating Income	-$44.25M	-$7.45M	-$12.86M	-$8.46M	-$48.03M	-$17.28M	-$22.62M
EBITDA	-$44.19M	-$7.40M	-$12.79M	-$8.39M	-$47.91M	-$17.13M	-$22.27M
Pretax Income	-$44.24M	-$7.45M	-$12.88M	-$8.46M	-$48.03M	-$16.63M	-$20.19M
Income Tax	$1.95M	—	—	—	$34.00K	—	—
Net Income	-$46.20M	-$7.45M	-$12.88M	-$8.29M	-$48.07M	-$16.63M	-$20.19M
Diluted EPS	—	-0.44	-0.75	—	—	-0.97	-1.18
Diluted Shares	—	17.12M	17.11M	—	—	17.11M	17.11M

RNA Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	—	$270.00M	—	—	$270.00M	$267.85M	—
Receivables	$0.00	—	—	—	—	$15.00M	—
Current Assets	$483.00K	$271.26M	—	—	$272.85M	$285.56M	—
Total Assets	$7.19M	$277.54M	—	—	$278.35M	$292.36M	—
Current Liabilities	$26.80M	$31.74M	—	—	$41.80M	$21.91M	—
Total Debt	$6.80M	$4.28M	—	—	$3.67M	$2.68M	—
Total Liabilities	$68.29M	$64.69M	—	—	$71.07M	$58.26M	—
Retained Earnings	—	—	—	—	—	$12.13M	—
Shareholders' Equity	-$61.11M	$212.85M	—	—	$207.29M	$234.10M	—
Working Capital	-$26.32M	$239.52M	—	—	$231.04M	$263.66M	—

RNA Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$8.26M	-$11.10M	-$11.91M	$1.13M	-$19.25M	-$31.14M	-$3.93M
Capital Expenditure	-$218.00K	—	—	-$300.00K	-$879.00K	-$2.10M	-$36.00K
Free Cash Flow	-$8.48M	-$11.10M	-$12.17M	$833.00K	-$20.13M	-$33.24M	-$3.96M
Depreciation & Amortisation	$58.00K	$53.00K	$79.00K	$69.00K	$122.00K	$151.00K	$343.00K
Stock-Based Compensation	$1.09M	$1.21M	$1.70M	$1.22M	$3.55M	$12.21M	$893.00K
Investing Cash Flow	-$218.00K	$0.00	-$266.00K	-$300.00K	-$879.00K	-$2.10M	-$191.59M
Financing Cash Flow	$8.48M	$11.10M	$12.17M	-$833.00K	$20.13M	$301.50M	$0.00
Net Change in Cash	—	—	—	—	—	$268.26M	-$195.51M

Market Snapshot

About

Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company combines the targeting ability of monoclonal antibodies with the precision of oligonucleotide therapies to address genetic diseases affecting muscle and other tissues. Avidity is advancing multiple programs for rare genetic diseases.